Navigation Links
Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease
Date:10/19/2010

search (www.michaeljfox.org).

"We are proud to play a key role in this potentially high-impact project," said Todd Sherer, Ph.D., vice president of research programs at The Michael J. Fox Foundation. "The Foundation continues to believe that trophic factors hold enormous potential to become transformative therapeutics for people with Parkinson's."

The first Phase 2 clinical trial of CERE-120, completed in November 2008, did not meet its pre-designated primary endpoint (Unified Parkinson's Disease Rating Scale- Motor Off at 12 months) although a clinically modest benefit was seen in improving motor performance and quality of life in Parkinson's disease patients, based on statistically significant differences in several secondary endpoints. Even greater improvement was seen following an analysis of all patients who were assessed under blinded conditions at 15 to 18 months post-treatment, including on the primary measure (UPDRS motor off at 18 months, p=0.025). Importantly, new scientific insight regarding degenerating dopamine neurons in the brains of advanced Parkinson's disease patients was gained from CERE-120-treated patients who died of unrelated causes, combined with the clinical results, led to important changes in CERE-120 dosing intended to significantly enhance its bioactivity and response to treatment. This revised dosing paradigm now targets both the terminals (or nerve endings) of the degenerating neurons in a site in the brain called the putamen, as well as the cell bodies of these neurons, located in another brain region called the substantia nigra.

"We are pleased to initiate a new controlled Phase 2b study that is statistically powered to demonstrate the efficacy of CERE-120," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "We continue to strongly believe that CERE-120 has the potential to improve the symptoms of Parkinson's disease while also delaying
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
2. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
3. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
4. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
5. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
6. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
7. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
8. Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
9. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
10. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
11. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
...   Sysmex America, Inc., a global leader in medical ... its 200th placement of Sysmex WAM ™ ... WAM is now connecting nearly 600 sites and approximately ... Canada. Sysmex WAM plays a key role in delivering ...
... March 20, 2012   A new Consumer Reports poll shows ... The poll was released just as House and Senate ... governing medical devices and at a time when the ... intense criticism.  The House Energy and ...
Cached Medicine Technology:Sysmex America Achieves Clinical Laboratory Connectivity Milestone 2Consumer Reports Poll: Americans Overwhelmingly Support Strong Medical Device Safety Oversight 2Consumer Reports Poll: Americans Overwhelmingly Support Strong Medical Device Safety Oversight 3Consumer Reports Poll: Americans Overwhelmingly Support Strong Medical Device Safety Oversight 4
(Date:4/24/2014)... substantial proportion of risk for developing autism spectrum disorders ... interconnected biological pathways, according to researchers from the Icahn ... broad study of almost 2,500 families in the United ... "Convergence of Genes and Cellular Pathways Dysregulated in Autism ... American Journal of Human Genetics on April 24. ...
(Date:4/24/2014)... Scientific research at UT Southwestern Medical Center previously ... completely, whereas the adult heart lacks this ability. New ... the heart loses its incredible regenerative capability in adulthood, ... , Yes, oxygen. It is well-known that a major ... throughout the body. But at the same time, oxygen ...
(Date:4/24/2014)... Changes in managing patients before, during and after colorectal ... readmission rates, according to researchers who led a study ... practice, called enhanced recovery, is easier on patients before ... evacuation that are typically prescribed. After surgery, patients are ... possible, leading to faster recoveries. , Among findings published ...
(Date:4/24/2014)... terminology, and the relevance of palliation in advanced ... randomized controlled trials (RCTs). This is the result ... Quality and Efficiency in Health Care (IQWiG), which ... Together with external experts, IQWiG analysed studies on ... malignant melanoma, and pancreatic cancer. For this purpose, ...
(Date:4/24/2014)... A Finnish team of researchers was the first in ... which is a tumour of the jaw. , Ameloblastoma ... recur after treatment. Ameloblastoma is most often found in ... by surgery, often resulting in tissue deficiencies in the ... suitable drug therapy could reduce the need for surgery ...
Breaking Medicine News(10 mins):Health News:Genetic alterations in shared biological pathways as major risk factor for ASD 2Health News:Oxygen diminishes the heart's ability to regenerate, researchers discover 2Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3
... Their growths also tend to be on the right side, requiring ... -- Among Hispanics, men are twice as likely as women to ... polyps, a new study in Puerto Rico has found. , The ... 56 percent more likely to have polyps than those younger than ...
... ... endometriosis, diagnosis and treatment options. , ... (PRWEB) May 2, 2010 -- The Endometriosis Foundation of America (EFA) ... Science of Endometriosis: Stem Cells to Radical Excision Surgery”, taking place in New York ...
... VANCOUVER, BRITISH COLUMBIA Reports have suggested that sleep ... (ASDs) are associated with challenging daytime behaviors. ... with ASD confirms these reports and will support the ... to improve behavior, according to researchers from Autism Speaks, ...
... ask children to fast overnight before a cholesterol test. New ... "Cholesterol testing can be very difficult for families," said Asheley ... presented Sunday, May 2 at the Pediatric Academic Societies (PAS) ... fast, this almost always means the child has to return ...
... majority of teens say they have never heard of acetaminophen ... with access to the label instructions despite having taken ... Medical Center Study assessing teens, health literacy. More than 60 ... heard of acetaminophen despite 21 percent of them having taken ...
... include Tylenol, Tylenol Plus, Motrin and Benadryl , SATURDAY, ... Friday recalled more than 40 of its liquid cold ... medications may not meet federal quality standards. , The ... Plus, Motrin, Zyrtec and Benadryl. These medications have been ...
Cached Medicine News:Health News:Colon Polyps More Common in Hispanic Men Than Women 2Health News:Endometriosis Foundation of America to Present Landmark Scientific Symposium in NYC 2Health News:Children may be able to eat before cholesterol test, study shows 2
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
A Biplane Pediatric TEE transducer....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... Super High Density, multi-frequency, linear ... the first company to introduce ... and, as a result, changed ... and true workhorse has withstood ...
Medicine Products: